SSG
FATE icon

Summit Securities Group’s Fate Therapeutics FATE Stock Holding History

Summit Securities Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-232
Closed -$1K – 720
2024
Q3 		$1K Buy
+232
New +$903 ﹤0.01% 509

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Summit Securities Group's FATE Position: Q4 2024 in Review

Summit Securities Group sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 232 shares — an estimated $1K sold.

Summit Securities Group first reported a position in FATE in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Summit Securities Group reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Summit Securities Group sold 232 Fate Therapeutics shares in Q4 2024, an estimated $1K.
  • Summit Securities Group first reported a position in Fate Therapeutics in Q3 2024 and held it in 1 quarter.
  • Summit Securities Group's Fate Therapeutics position peaked at $1K in Q3 2024.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.